Dr. Marrazzo is the Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health, where she oversees a $6.3 billion budget that supports research to advance the understanding, diagnosis, and treatment of infectious, immunologic, and allergic diseases. Prior to taking that position in 2023, she was the C. Glenn Cobbs Endowed Chair and Director of the Division of Infectious Diseases at the University of Alabama at Birmingham Heersink School of Medicine (UAB). She is a Fellow of the American College of Physicians and of the Infectious Diseases Society of America (IDSA), and was Treasurer of the IDSA from 2021-2023, having served on the board since 2018. She was Chair of the American Board of Internal Medicine Council from 2015-2018.
Dr. Marrazzo has a broad research portfolio that includes the relationships between the vaginal microbiome and female reproductive tract infections, HIV pre-exposure prophylaxis, hormonal contraception, and risk of STI/HIV acquisition. She led UAB’s participation in the RECOVER trial, funded by NIH to study post-acute sequelae of SARS-CoV-2 infection, and a large clinical trial of the meningococcal Group B vaccine rMenB+OMV NZ (Bexsero) to prevent gonococcal infection. She chaired the Biomedical Science Committee of the HIV Prevention Trial Network, the group tasked with integrating the biomedical science agenda across numerous clinical trials of antiretroviral prevention agents. She was also a Co-PI of the NIH-funded Infectious Disease Clinical Research Consortium that leads the Vaccine Treatment and Evaluation Units as well as NIH-funded STI clinical trials. She has been a leading voice in educating colleagues, the community, and the media during the COVID-19 pandemic.
